Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 3 · 60%Moderate 2 · 40%High 0 · 0%

50% or greater reduction in seizure frequency · people with drug‐resistant focal epilepsy

Brivaracetam probably leads to higher 50% or greater reduction in seizure frequency (responder rate) compared with placebo (moderate certainty).

1 finding from 1 review

Brivaracetam add‐on therapy for drug‐resistant epilepsy 2022 · Cochrane Headline outcomes only
RR 1.81 [1.53, 2.14]
6 studies · 2411 participants
Moderate

Seizure freedom · people with drug‐resistant focal epilepsy

Brivaracetam may leads to higher seizure freedom compared with placebo (low certainty).

1 finding from 1 review

Brivaracetam add‐on therapy for drug‐resistant epilepsy 2022 · Cochrane Headline outcomes only
RR 5.89 [2.3, 15.13]
6 studies · 2411 participants
Low

Treatment withdrawal · people with drug‐resistant focal epilepsy

Brivaracetam showed no clear difference in treatment withdrawal compared with placebo (low certainty).

1 finding from 1 review

Brivaracetam add‐on therapy for drug‐resistant epilepsy 2022 · Cochrane Headline outcomes only
RR 1.27 [0.94, 1.74]
6 studies · 2411 participants
Low

Withdrawals due to adverse events · people with drug‐resistant focal epilepsy

Brivaracetam may leads to higher proportion of participants who experienced adverse events leading to… compared with placebo (low certainty).

1 finding from 1 review

Brivaracetam add‐on therapy for drug‐resistant epilepsy 2022 · Cochrane Headline outcomes only
RR 1.54 [1.02, 2.33]
6 studies · 2411 participants
Low

Adverse events as N of participants with at least one adverse event objective · people with drug‐resistant focal epilepsy

Brivaracetam showed no clear difference in proportion of participants who experienced any adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Brivaracetam add‐on therapy for drug‐resistant epilepsy 2022 · Cochrane Headline outcomes only
RR 1.08 [1, 1.17]
5 studies · 2011 participants
Moderate